Back to Journals » Drug Design, Development and Therapy » Volume 12

RETRACTED ARTICLE: Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation

Authors Zhou X, Tao H, Shi KH

Received 21 July 2017

Accepted for publication 18 October 2017

Published 18 December 2017 Volume 2018:12 Pages 1—8

DOI https://doi.org/10.2147/DDDT.S146925

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Anastasios Lymperopoulos



This paper has been retracted.

Zhou X, Tao H, Shi KH. Drug Des Devel Ther. 2018;12:1–8.

The Editor and Publisher of Drug Design, Development and Therapy wish to retract the published article. Concerns were raised regarding the alleged duplication of images in Figure 5 with the same images from other unrelated articles. Specifically,

The authors did not respond to our queries and no explanation for the alleged image duplication was provided. The Editor requested to retract the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Creative Commons License © 2017 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.